Asana BioSciences , LLC– Protocol ASN002AD -201 Page 2 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  TABLE OF CONTENT S 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  2 
PROTOCOL VERSION HISTORY  ................................ ................................ ...............................  6 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................  8 
SIGNATURE [CONTACT_1783]  ................................ ................................ ................................ ......................  9 
PRINCIPAL/QUALIFIED INVESTIGAT OR SIGNATURE [CONTACT_1783]  ................................ ..........  [ADDRESS_486580] OF ABBREVIATIONS  ................................ ................................ ................................ ....... 11 
1 PROTOCOL SUMMARY  ................................ ................................ ............................  13 
1.1 Synopsis  ................................ ................................ ................................ ........................  13 
1.2 Study Diagram  ................................ ................................ ................................ ..............  22 
1.3 Schedule of Events  ................................ ................................ ................................ ........  22 
2 INTRODUCTION  ................................ ................................ ................................ ........  25 
2.1 Background  ................................ ................................ ................................ ...................  25 
 Atopic Dermatitis  ................................ ................................ ................................ .. 25 
 ASN002 in Atopic Dermatitis  ................................ ................................ ................  25 
 Study Rationale  ................................ ................................ ................................ ..... 26 
2.2 Risk/Benefit Assessment  ................................ ................................ ...............................  [ADDRESS_486581] Treatment 
Interruption/Discontinuation  ................................ ................................ .........................  [ADDRESS_486582]  ................................ ................................ ...............  32 
5 STUDY POPULATION  ................................ ................................ ...............................  33 
5.1 Inclusion Criteria  ................................ ................................ ................................ ...........  33 
5.2 Exclusion Criteria  ................................ ................................ ................................ .........  34 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 3 of 76  
Protocol version 3.0: [ADDRESS_486583] to Follow -Up ................................ ................................ ................................ . 38 
5.4 Screen Failures  ................................ ................................ ................................ ..............  39 
6 TREATMENT  ................................ ................................ ................................ ..............  40 
6.1 Study Products Administered  ................................ ................................ ........................  40 
 Missed or Vomited Doses ................................ ................................ ......................  40 
 Duration of Treatment  ................................ ................................ ..........................  41 
6.2 Preparation/Handling/Storage/Accountability  ................................ ..............................  41 
 Preparation/Storage/Handling  ................................ ................................ .............  [ADDRESS_486584] Gastric pH  ................................ ........  45 
 Study Restrictions ................................ ................................ ................................ .. 46 
7 STUDY ASSESSMENTS AND PROCEDURES  ................................ ........................  47 
7.1 Efficacy Assessments  ................................ ................................ ................................ .... 47 
 Eczema Area and Severity Index  ................................ ................................ ...........  47 
 Investigator Global Assessment  ................................ ................................ ............  47 
 SCORing Atopic Dermatitis  ................................ ................................ ..................  47 
 Body Surface Area  ................................ ................................ ................................  47 
 Pruritus Numeric Rating Scale  ................................ ................................ .............  48 
 5D-Pruritus Scale  ................................ ................................ ................................ . 48 
7.2 Quality -of-Life Assessments  ................................ ................................ .........................  48 
 Patient -Oriented Eczema Measure  ................................ ................................ ....... 48 
 Dermatology Life Quality Index Questionnaire  ................................ ...................  49 
7.3 Safety Assessments  ................................ ................................ ................................ ....... 49 
 Vital Signs  ................................ ................................ ................................ .............  49 
 Physical Examination  ................................ ................................ ...........................  49 
 Brief Physical Examination  ................................ ................................ ..................  50 
 Clinical Laboratory Tests  ................................ ................................ .....................  50 
 Electr ocardiogram  ................................ ................................ ................................  51 
7.4 Pharmacokinetic and Pharmacodynamic Assessments  ................................ .................  52 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 4 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Pharmacokinetics Assessments  ................................ ................................ .............  52 
 Pharmacodynamics Assessments  ................................ ................................ ..........  52 
 PK/PD Relationship Assessments  ................................ ................................ .........  52 
 Skin Biopsies  ................................ ................................ ................................ .........  53 
7.5 Other Assessments  ................................ ................................ ................................ ........  53 
 Medical Photography ................................ ................................ ............................  53 
7.6 Adverse Events and Serious Adverse Events  ................................ ...............................  54 
 Definition of Adverse Event  ................................ ................................ ..................  54 
 Definition of Treatment -Emergent Adverse Event  ................................ ................  54 
 Definition of Serious Adverse Event  ................................ ................................ ..... 54 
 Classification of an Adverse Event  ................................ ................................ ....... 55 
 Time Period and Frequency for Event Assessment and Follow -Up .....................  56 
 Adverse Event Reporting ................................ ................................ .......................  56 
 Serious Adverse Events Reporting  ................................ ................................ ........  57 
 Pregnancy Reporting  ................................ ................................ ............................  58 
 Overdose  ................................ ................................ ................................ ...............  58 
8 STATISTICAL CONSIDERATIONS  ................................ ................................ ..........  59 
8.1 Sample Size Determination  ................................ ................................ ...........................  59 
8.2 Populations for Analyses  ................................ ................................ ..............................  59 
8.3 Statistical Analyses  ................................ ................................ ................................ ....... 60 
 General Approach  ................................ ................................ ................................ . 60 
 Efficacy Analyses  ................................ ................................ ................................ .. 60 
 Safety Analyses ................................ ................................ ................................ ...... 61 
 Pharmacokinetic Analyses  ................................ ................................ ....................  61 
 Pharmacodynamic Analyses  ................................ ................................ .................  62 
 Other Analyses  ................................ ................................ ................................ ...... 62 
 Planned Interim Analysis  ................................ ................................ ......................  62 
9 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS  .... 63 
9.1 Local Regulations/Declaration of Helsinki  ................................ ................................ ... [ADDRESS_486585] Keepi[INVESTIGATOR_007]  ................................ ................................ .............  65 
9.9 Protocol Deviations  ................................ ................................ ................................ ....... 66 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 5 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  9.10  Publication Policy  ................................ ................................ ................................ .........  66 
10 REFERENCES  ................................ ................................ ................................ ..............  67 
APPENDIX A: Diagnostic Criteria for Atopic Dermatitis  ................................ ...........................  69 
APPENDIX B: Eczema Area and Severity Index  ................................ ................................ ........  70 
APPENDIX C: vIGA -ADTM ................................ ................................ ................................ .........  71 
APPENDIX D: Scoring Atopic Dermatitis - SCORAD  ................................ ...............................  72 
APPENDIX E: Patient -Oriented Eczema Measure  ................................ ................................ ...... 73 
APPENDIX F: Patient -Oriented Eczema Measure  ................................ ................................ ....... 74 
APPENDIX G: Dermatology Life Quality Index  ................................ ................................ .........  [ADDRESS_486586] OF TABLES  
 
Table 1: Schedule of Events  ................................ ................................ ................................ .........  23 
Table 2. Study Products  ................................ ................................ ................................ ................  40 
Table 3. Prohibited Therapi[INVESTIGATOR_388113]  ................................ ................................ ................  45 
Table 4. Examples of H2 antagonists and Proton Pump Inhibitors  ................................ ..............  46 
Table 5: Clinical Laboratory Testing  ................................ ................................ ............................  [ADDRESS_486587] OF FIGURES  
 
Figure 1: Study Diagram  ................................ ................................ ................................ ...............  22 
Figure 2: Pruritus Numeric Rating Scale  ................................ ................................ ......................  48 
 
 
 
 
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 7 of 76  
Protocol version 3.0: [ADDRESS_486588] typographical erro rs.  
-Synopsis, Schedule of event (footnote), 
Sections 5.3.1, 6.4.[ADDRESS_486589] 
discontinuation is required or not. 
Specification s with regards to how to 
handl e missing data in the statistical 
analysis ha ve been made in the statistical 
section s.  
 
-Section 7.1.4, the following " ([excluding 
palms, back of the hands, soles, scalp, 
genitals, and folds])" was removed as it 
was included in the protocol in error.  
 
-Syno psis, s econdary pharmacokinetic 
endpoint revised to be consistent with 
section 3.  
-Section 5.2, criterion # 16, bullet 
numbering corrected to be consistent with 
the numbering in the synopsis.  
-Section 5.2, criterion # 3 7 (in  version 
1.0), revised to be consistent with 
criterion in the synopsis.  
-Section 9.10, section title was corrected.  
-Minor typographical errors corrected 
throughout the document.  
3.0 / 07 February  
2019  - To revise the inclusion criteri on 
related to body mass index (BMI) in 
order to  allow wider pool of subjects  
access to the tri al. - Synopsis  and Section 5.1 , inclusion 
criteri on #7, BMI was revised to ≤ 38 
kg/m2. 
   
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 8 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  STATEMENT OF COMPLIANCE  
The trial will be conducted in accordance with the protocol, International Council for 
Harmonisation (ICH) Good Clinical Practice (GCP), the Declaration of Helsinki, and applicable 
local regulations. The principal investigator [INVESTIGATOR_388114] d eviation from, or changes 
to the protocol will take place without prior agreement from the sponsor and documented approval 
from the institutional review board (IRB)  / ethic committee (EC) , except where necessary to 
eliminate an immediate hazard(s) to the t rial subjects. All personnel involved in the conduct of this 
study have completed ICH GCP training.  
 
The protocol, informed consent form(s), recruitment materials, and all subject materials will be 
submitted to the IRB /EC for review and approval. Approval of both the protocol and the consent 
form must be obtained before any subject is enrolled. Any amendment to the protocol will require 
review and approval by [CONTACT_1201] /EC before the changes are implemented to the study. All changes 
to the consent form will be  IRB/EC approved.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 10 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  PRINCIPAL/QUALIFIED INVESTIGATOR SIGNATURE [CONTACT_388166]:   
 
 
Signature:   [CONTACT_1782]:   
   
  (DD-MMM -YYYY)  
 
Institution Name:    
 
 
 
[CONTACT_74994] [CONTACT_27616], I agree to personally supervise the conduct of this study at my study site and 
to ensure its conduct is in compliance with the protocol, informed consent, institutional review 
board/ independent ethics committee procedures, instructions from sponsor’s  representatives, 
the Declaration of Helsinki, ICH GCP guidelines , applicable Canadian regulations, applicable 
European regulations, applicable [LOCATION_002] federal regulations, and local regulations 
governi ng the conduct of clinical studies.  
 
 
  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 11 of 76  
Protocol version 3.0: [ADDRESS_486590]  
ITT intent -to-treat (population)  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 12 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  IWRS  Interactive Web Response System  
LDH  lactate dehydrogenase  
LDL  low-density lipoproteins  
LMW  low molecular weight  
JAK janus kinase  
Mapi  [INVESTIGATOR_388115] -inflammatory drug  
NYHA  [LOCATION_001] Heart Association  
OLE  open label extension study  
PD pharmacodynamic  
PK pharmacokinetic  
PLT platelets  
POEM  Patient -Oriented Eczema Measure  
PP per-protocol (population)  
[COMPANY_003] purified protein derivative  
PUVA  psoralen -UV-A 
QC quality control  
RBC  red blood cell (count)  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAF safety (population)  
SAP statistical analysis plan  
SCORAD  SCORing Atopic Dermatitis  
SD standard deviation  
SYK  spleen tyrosine kinase  
TB tuberculosis  
TEAE  treatment -emergent adverse event  
ULN  upper limit of normal  
UV ultraviolet  
VTE  venous thromboembolic event  
WBC  white blood cell (count)  
WHO  World Health Organization  
WOCBP  women of childbearing potential  
 
  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 13 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  1 PROTOCOL SUMMARY  
1.1  Synopsis  
Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
Title of Study:  
A Randomized, Double -Blind, Placebo -Controlled, Phase 2 b Study to Evaluate the Efficacy, Safety, 
Tolerability, and Pharmacokinetics of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis  
Phase of Development:  
Phase 2 b 
Study Center(s):  
Approximately 50 study centers located in the [LOCATION_002] , Canada , and [LOCATION_013]  will participate in 
this study.  
Number of Subjects (planned):  
Approximately 220 subjects will be included in this study to reach 160 evaluable subjects.  
Duration of Study:  
The maximum study duration per subject is up to 20 weeks (including up to 4 weeks for the screening 
period, up to 12 weeks for the treatment period, and up to 4 weeks for the follow -up period).   
Investigational Product, Dosage, and Mode of Administration:   
ASN002 40, 60, or 80 mg or placebo orally administered once daily  for 12 weeks . ASN002 will be 
available in 20 -mg strength tablets.  
Subjects will be  randomized in a 1:1:1:1 ratio. Randomization will be stratified by [CONTACT_73296] ([Eczema Area and Severity Index (EASI) = 16.0-21.2] vs. [EASI = 21.3-29.9] vs. 
[EASI  = ≥ 30.0]) and biopsy collection.    
Objectives:  
Primary:  
• To evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD)  
Secondary:  
• To evaluate the safety and tolerability of ASN002 in subjects with moderate to severe AD 
• To evaluate the pharmacokinetic (PK) profile of ASN002 in subj ects with moderate to severe AD 
Exploratory:  
• To assess population PK of ASN002 in AD subjects via a population PK analysis approach  
• To evaluate pharmacodynamic (PD) and biomarkers for evidence of drug activity in subjects with 
moderate to severe AD 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 14 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
• To explore the relationships between PK exposure and clinical measurement (e.g., biomarker, 
efficacy , and safety) as appropriate  
Endpoint s: 
Primary Endpoint:  
• Change from baseline in EASI score at Week 12  
Secondary Endpoints : 
Secondary efficacy endpoints include:  
• Change from baseline in EASI score at Weeks 2, 4, and 8  
• Percent change from baseline in EASI score at Weeks 2, 4, 8, and 12  
• Proportion of subjects with at least a 50% reduction from baseline in EASI (EASI50) at Weeks  2, 
4, 8, and 12  
• Proportion of subjects achieving at least a 75% reduction from baseline in EASI (EASI75) at 
Weeks  2, 4, 8, and 12  
• Proportion of subjects achieving at least a 90% reduction from baseline in EASI (EASI90) at 
Weeks  2, 4, 8, and 12  
• Time to achieve EASI50, EASI75, and EASI90  relative to baseline.  
• Proportion of subjects achieving at least a 2 -grade reduction from baseline to clear (0) or almost 
clear (1) i n Investigator’s Global Assessment (IGA) at Weeks  2, 4, 8, and 12  
• Proportion of subjects achieving at least a 2 -grade reduction from baseline in IGA at Weeks  2, 4, 
8, and 12  
• Proportion of subjects achieving an IGA of clear (0) or almost clear (1) at Weeks  2, 4, 8, and 12  
• Change from baseline in SCORing Atopic Dermatitis  (SCORAD) at Weeks  2, 4, 8, and 12  
• Change from baseline in 5 -D Pruritus Scale at Weeks  2, 4, 8, and 12  
• Change and percent change from baseline in single daily timepoint pruritus Numeric Rating Scale 
(NRS) at Week  1 
• Change and percent change from baseline in weekly average of the peak daily pruritus NRS at 
Weeks  1, 2, 4, 8, and 12   
• Proportion of subjects achieving at least a 4 -point reduction from baseline  in wee kly average of  
the peak  daily pruritus NRS at Weeks 1,  2, 4, 8, and 12  
• Change and percent change from baseline in Body Surface Area (BSA) involved with AD at 
Weeks  2, 4, 8, and 12  
• Change from baseline in Patient -Oriented Eczema Measure (POEM) at Weeks  2, 4, 8, and 12  
• Change from baseline in Dermatology Life Quality Index (DLQI) at Weeks  2, 4, 8, and 12  
Secondary safety endpoints include:  
• Number of treatment -emergent adverse events (TEAEs)  
• Number of drug-related TEAEs   
• Proportion of subjects withdrawing from worsening AD at Weeks 2, 4, 8, and 12  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 15 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
• Changes in vital signs, physical examinations, electrocardiogram (ECG), and safety laboratory  
tests  
Secondary pharmacokinetic endpoint include s: 
• Measurement of plasma concentrat ions of ASN002 in all subjects recei ving ASN002 treatment  
Exploratory Endpoints:  
Exploratory endpoints include:  
• Change from baseline in expression levels and kinase activity of key disease pathways in skin 
biopsies, such as Th2 and other T helper cell axes 
• Changes from baseline in cellular infiltrates of T -cells and dendritic cells  
• Changes from baseline in epi[INVESTIGATOR_388116] (epi[INVESTIGATOR_207891], ki67 , and K16 
expression)  
• Changes from baseline in mRNA and protein expression of differentiation markers  
• Changes in inflammatory measures in peripheral blood using proteomics  
• Characterization of population PK parameters via nonlinear mixed -effects modeling  
• Changes from baseline in clinical safety, efficacy , and biomarker measurements i n relationship to 
PK exposure  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 16 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
Study Design:  
Approximately 220 subjects with moderate to severe AD (as defined by a BSA involved with AD of 
≥ 10%, an EASI ≥ 16, and an IGA ≥ 3  at Day 1 ) will be included in this randomized, double -blind, 
placebo -controlled, multicenter, Phase 2 b study.  
All subjects will sign an informed consent and undergo screening for study eligibility. After a screening 
period of no more than 30 days (from Day -30 to Day  -1), eligible subjects will be randomized (1:1:1:1) 
on D ay 1 to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks, followed 
by a 4 -week follow up period for subjects not participating in the open label extension (OLE) study. For 
scheduled study visits, s ubjects will come to the study centers on seven occasions: screening;  Day 1; 
Weeks 2, 4, 8, and 12; and Week  16/early termination (ET) for subjects not participating in the OLE 
study.  
Efficacy will be assessed using IGA, EASI, SCORAD, BSA, pruritus NRS  (daily) , and 5 -D pruritus 
scale. Quality of life will be evaluated using  POEM and DLQI.  
Safety will be assessed by [CONTACT_20721] ( AEs), physical examination, vital signs, [ADDRESS_486591] -dose PK blood samples will be collected from all subjects on a sparse sampling schedule 
on Day  1 and Weeks 2, 4, 8 and 12  (or ET visit, if applicable) .  
At selected study centers, in a subset of approximately 68 subjects who consent , PD blood samples will 
be collected pre -dose on Day 1 and Week 12  (or ET visit, if applicable) . PD samples will be obtai ned 
from the same subjects who consent to biopsy collection.  An additional PD blood sample will be 
collected at Week 4 in subjects who also consent to four skin biopsies.  
At selected study centers, in a subset of approximately 68 subjects who consent , thre e or four skin 
biopsies will be collected during this study. Two 4.5 -mm punch biopsies (one from lesional skin and one 
from adjacent nonlesional skin) will be collected at Day  1, and one 4. 5-mm punch biopsy will be 
collected from the same lesional skin (outside the scar of the previous biopsy , at least [ADDRESS_486592] from 
the previous scar ) at Week 12 (or ET visit , if applicable). In addition, one 4.5 -mm punch biopsy will be 
collected from the same  lesional skin (outside the scar of the previous biopsy , at least [ADDRESS_486593] from 
the previous scar ) at Week [ADDRESS_486594] AD involvement will be taken to illustrate any visible clinical change.   
Inclusion/Exclusion Criteria:  
Inclusion criteria:  
1. Male or female subject, aged [ADDRESS_486595] 4 weeks before scre ening (information obtained from medical chart or subject’s 
physician, or directly from the subject).  
4. Subject has an EASI score ≥ 16 at Day 1.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 17 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
5. Subject has moderate to severe atopic dermatitis at Day 1, as defined by [CONTACT_388133] ≥ 3.  
6. Subject has atopic dermatiti s covering ≥ 10% of the BSA on Day 1. 
7. Subject has a body mass index (BMI) ≤ 3 8 kg/m2. 
8. Subject has a history of inadequate response to topi[INVESTIGATOR_388117] 1 year before the screening visit (informatio n obtained from medical chart 
or subject history).  
9. Subject has been using an emollient (except those containing urea)  either  once daily or twice  daily  
for at least 1  week prior to Day 1  and agrees to continue using that same emollient, daily and at the 
same frequency, throughout the study.  Note: On the day of scheduled visits, subject s cannot  apply 
emollient before their scheduled visit time.    
10. For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: 
the subject must agree to use a  highly  effective contraceptive method from at least [ADDRESS_486596] administration. Highly e ffective contraceptive 
methods include hormonal contraceptives (combined oral c ontraceptive, patch, vaginal ring, 
injectable, or implant), intrauterine devices or intrauterine systems, vasectomized partner(s), tubal 
ligation, or double  barrier method s of contraception ( barrier methods include male condom, female 
condom, cervical cap,  diaphragm, contraceptive sponge) in conjunction with spermicide.  
Note: Subjects must have been on a stable dose of hormonal contraceptives for at least 4 weeks 
before Day  1.  
Note: The above list of contraceptive methods does not apply to subjects who ar e abstinent for at 
least 4 weeks before Day 1 and will continue to be abstinent from penile -vaginal intercourse 
throughout the study.  The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the clinical trial and the pref erred and usual lifestyle of the participant.  
Note: For countries where double barrier methods are not accepted as highly  effective contraception, 
then this option must not be considered.  
Note: A woman of nonchildbearing potential is as follows:  
a. Woman who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or 
bilateral salpi[INVESTIGATOR_1656]);  
b. Woman who has had a cessation of menses for at least 12 months without an alternative 
medical cause, and a follicle -stimulating hormone (FSH) test confirming nonchildbearing 
potential (refer to laboratory reference ranges for confirmatory levels).  
11. For men involved in any sexual intercourse that could lead to pregnancy, subject must agree to use 
one of the  highly  effective contraceptive methods listed in Inclusion Criterion #10, from Day  [ADDRESS_486597] is willing to participate and is capable of giving informed consent. Note: Consent must be 
obtained prior to any study -related procedures.  
14. Subjects must be willing to comply  with all study procedures and must be available for the duration 
of the study.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 18 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
Exclusion criteria:   
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during 
the study.  
2. Subject has clinically infected atopic dermatit is. 
3. Subject has a history of skin disease or presence of skin condition that, in the opi[INVESTIGATOR_1070], would interfere with the study assessments.  
4. Active infection, including skin in fection, requiring treatment.  
5. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day  1. Subjects 
with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or 
localized carcinoma in situ of the cervix are not to be excluded.  
6. Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs 
abnormality that would, in the opi[INVESTIGATOR_871], put the subject at undue risk or interfere 
with interpretation of study results.  
7. Subject has 12 -lead ECG abnormaliti es considered by [CONTACT_388134] F ≥ 450 milliseconds, regardless of clinical significance, at screening. Abnormal ECG may be 
confirmed with one repeat assessment. For subjects with QTcF≥[ADDRESS_486598] has a history of congestive heart failure [LOCATION_001] Heart Association (NYHA) class III or 
IV. 
9. Subject has a history of erythrodermic, refractory or unstable skin disease, including AD, that 
requires frequent hospi[INVESTIGATOR_4355]/or frequent intravenous treatment for skin infections  over the 
last year 
10. Subject has a history of eczema herpeticum  within 12 months, and/or a history of [ADDRESS_486599] has a history of recurrent venous thromboembolic event (VTE) (>=2)  
12. Subject has experienced any of the following within the last 6 months prior to Day 1: VTE  
myocardial infarction, angioplasty, or cardiac stent placement, unstable ischemic heart disease, or 
stroke.  
13. Subject had other major surgery within [ADDRESS_486600] has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core 
antigens (anti -HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) at the 
screening visit.  
16. Presence of an y of the following laboratory abnormalities at the screening visit:  
a. Hemoglobin < 11 g/dL;  
b. White blood cell (WBC) < 3.0 x 103 /μL; 
c. Platelet count < 125 x 103 /μL; 
d. Neutrophils < 1.8 x 103 /μL; 
e. Lymphocytes < 1.0 x 103 /μL; 
f. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x the upper  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 19 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
limit of normal (ULN) ; 
g. Total bilirubin > 1.[ADDRESS_486601] (except for elevated indirect bilirubin secondary to Gilbert’s  
syndrome);  
h. Creatinine > ULN.  
17. Subjects has uncontrolled hypertension within the last 1 month prior to screening or blood pressure 
at screening of systolic blood pressure >1 60 mm Hg or diastolic BP >[ADDRESS_486602] has a known active tuberculosis or a positive tuberculosis ( TB) infection test.  Subject will 
be evaluated for latent TB infection with a purified protein derivative ([COMPANY_003]) test or a QuantiFERON -
TB Gold test. Subjects who demonstrate evidence of latent TB infection (either [COMPANY_003] ≥[ADDRESS_486603], irrespective of bacille Calmette -Guérin 
vaccination status) will only be allowed to participate in the study if there is documented evidence 
of a completed adequate treatment course for latent TB (with negative chest x -ray findings for ac tive 
TB). 
19. Subject has difficulty swallowing medications, or known history of malabsorption syndrome.  
20. Subject has a history of recurrent gastroesophageal reflux disease  (GERD ) requiring the use of 
proton pump inhibitors within the last month.  
21. Subject has a  known history of diverticulitis.  
22. Subject has uncontrolled diabetes.  
23. Any medical or psychiatric condition which, in the opi[INVESTIGATOR_12440]’s 
medical monitor, would place the subject at risk, interfere with participation in the study , or interfere 
with the interpretation of study results.  
24. Subject has used dupi[INVESTIGATOR_207928] [ADDRESS_486604] has received any UV -B phototherapy (including tanning beds) or excimer laser within 
[ADDRESS_486605] has had psorale n-UV-A (PUVA) treatment within [ADDRESS_486606] has used systemic treatments (other than biologics) that could affect atopic dermatitis less 
than 4 weeks prior to Day 1 (e.g., retinoids, calcineurin inhibitors, methotrexate, cyclos porine, 
hydroxycarbamide [hydroxyurea], azathioprine, oral/injectable corticosteroids). Note: Intranasal 
corticosteroids, eye drops containing corticosteroids, and inhaled corticosteroids for stable medical 
conditions are allowed.  
33. Subject has received any  marketed or investigational biological agent within 12 weeks or 5 half -
lives (whichever is longer) prior to Day 1.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 20 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
34. Subject is currently receiving any other medication for AD.  
35. Subject is currently receiving a nonbiological investigational product or device or has received one 
within [ADDRESS_486607] has received a live attenuated vaccine within 4 weeks prior to Day 1 or plans to receive a 
live attenuated vaccine during the study and up to 4 weeks or 5 half -lives (of the study product), 
whichever is longer, after the last study product administration.  
38. Subject has used ASN002.  
39. Subject had prior treatment with  a systemic SYK or JAK inhibitor for which the subject received no 
clinical benefit  in the opi[INVESTIGATOR_871] , or the subject relapsed whilst on therapy , or was 
withdrawn for safety  reasons . 
40. Subject has a known hypersensitivity to ASN002 or its excipi[INVESTIGATOR_840].  
41. Subject has a known history of clinically significant drug  or alcohol abuse in the last year prior to 
Day 1. 
42. Subject has a close affiliation with the investigator (e.g., a close relative) including any study staff 
of the sites or persons working at the CRO , or subject is an employee of the sponsor.  
43. Subject is ins titutionalized because of legal or regulatory order.  
44. Only f or subjects consenting to biopsies:  
a. Subject has a history of an allergic reaction or significant sensitivity to lidocaine or other 
local anesthetics;  
b. Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites;  
c. Subject is taking anticoagulant medication, such as heparin, low molecular weight 
(LMW) -heparin, warfarin, antiplatelets (except low -dose aspi[INVESTIGATOR_388118]), 
within 2 weeks prior to Day 1,  or has a contraindication to skin biopsies. Nonsteroidal anti -
inflammatory drugs [NSAIDs] will not be considered antiplatelets and will be allo wed.  
Statistical methods:   
Continuous variables will be summarized in tables and will include the number of subjects, mean, 
standard deviation  (SD) , percent of coefficient of variance (CV%),  median, minimum, and maximum. 
Categorical variables will be pres ented in tables as frequencies and percentages. A statistical analysis 
plan (SAP) will provide additional details on the approach to the analysis and data displays.  
Efficacy Analyses:  
The primary efficacy endpoint will be analyzed using a repeated measures analysis of covariance on 
change -from -baseline variable to compare the time profile between treatments where the visit will be the 
time factor; and the stratification factors, treatme nt group, and interaction term for treatment -by-visit 
will be the fixed effects and the baseline value will be the covariate. An unstructured variance -covariance 
matrix will be used.  
For categorical efficacy endpoints involving proportions of IGA, EASI and NRS (e.g. the proportion of 
subjects achieving at least a 2 -grade reduction from baseline to clear (0) or almost clear (1) in IGA at 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 21 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
Asana BioSciences, LLC  Name [CONTACT_211725]: ASN002  Name [CONTACT_3261]: 
ASN002  
week 12), a Cochran Mantel Hansel test (CMH) cont rolling for the stratification variables will be 
performed.  
 
For the primary endpoint of change -from -baseline in EASI at Week 12, a Bonferroni adjustment will be 
done to test the three comparisons of interest (40  mg vs. Placebo, 60  mg vs. Placebo and 80  mg vs. 
Placebo) at nominal alpha of 0.0167.  
Safety Analyses:  
The safety analysis will include reported AEs and other safety information (i.e., clinical laboratory 
evaluations, vital signs, physical examination, and 12 -lead ECG results). A summary of safety results 
will be presented for each treatment group.  
PK Analyses:  
ASN002  concentration data  will be summarized based on no minal timepoints using descriptive statistics , 
such as mean, SD, CV%, median, minimum and maxi mum .  
Population PK analysis will be performed using nonlinear mixed -effects modeling approach with first -
order conditional methods. This analysis may be combined with PK concentrations from other clinical 
trials in healthy and AD subjects as appropriate.  
PD An alyses:  
Biomarker levels will be compared to placebo adjusted change from baseline over time for each 
treatment group, and the parameters will be summarized by [CONTACT_388135].  
PK/PD Analyses:  
PK-efficacy , PK-safet y and PK -biomarkers  relationships will be explored using linear regression, loess 
plots, Hills functions, or logistic regression, as appropriate.  
Sample Size Consideration:  
Using the following assumptions: a change -from -baseline in EASI at week [ADDRESS_486608], we  would need 40 subjects per group in 
order to achieve a power of 92%  on the primary efficacy endpoint.  
 
Moreover, with [ADDRESS_486609] 80% power to show a statistically significant 
difference between the higher dosing group and placeb o in IGA responses (one of the key secondary 
efficacy endpoint), assuming a response of 37.5% vs. 11.1% in the higher dosing and placebo groups, 
respectively, using an alpha of 5%.   
 
Thus, assuming about 15% dropout rate, [ADDRESS_486610] a minimum of 46 subjects  per group to evaluate efficacy with 
adequate power . 
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 22 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  1.2  Study Diagram  
Figure 1: Study Diagram  
 
1.[ADDRESS_486611] fulfills all inclusion criteria and no exclusion criteria, 
he or she may be included in the study.  
 
Table  1 provides a description of the procedures to be performed at each visit.  
 
If assessments are scheduled at the same time, then the assessments should occur in the following 
order:  
• Vital signs  (within 1 hour of dosing)     
• 12-lead ECG  
• Blood draw s for PK  and PD samples (time window vs drug administration detailed in  footer 
of  Table 1) 
 

Asana BioSciences , LLC– Protocol ASN002AD -201 Page 25 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  2 INTRODUCTION  
2.1  Background  
 Atopic Dermatitis  
Atopic dermatitis (AD) is a chronic inflammatory skin disease. Inflammation, pruritus, papules, 
lichenification, excoriations, xerosis and oozing  clinically characterize AD. (1) Onset typi[INVESTIGATOR_388119], however, late onset can also occur. (2) Atopic 
dermatitis affects 10 -20% of children and 1 -3% of adults .(2, 3)  Moreover, recent studies suggest 
that the prevalence of AD in adults could be much higher. (4). Prevalence has also been observed 
to be higher in industrialized cou ntries, suggesting, at least partially, an environmental link. (5) The 
quality of life and psychological state of patients with AD, as well as the parents of patients can 
be greatly impacted by [CONTACT_53220]. (6, 7)   Pruritus prevalence in AD patients is greater than 80% 
and greatly impairs their quality of life by [CONTACT_388136]. (8) 
 
It is a heterogeneous disease with a wide spectrum of clinical phenotype and a complex 
pathophysiolo gy.(9, 10)  The precise etiology of AD remains unclear but is likely to be 
multifactorial in nature, involving genetics, abnormalities in the skin barrier, immune system 
defects, and environmental triggers (e .g., allergens, irritants, microbes, diet, stress, air quality). (3, 
11)   
 
In recent years, the understanding of the  clinical characterization of AD phenotypes and molecular 
mechanisms of the disease has advanced greatly giving  hope for the development of  new 
therapeutic agents. (5, 10, 12, 13)  Janus kinase (JAK) and Spleen tyrosine kinase (SYK) are 
tyrosine kinases that have been shown to be implicated in the pathogenesis of various types of 
autoimmune and inflammatory diseases .(14, 15)  It is understood that AD is primarily a T cell -
driven disease. (16) Atopic dermatitis was shown to h ave a strong Th2 response where IL -[ADDRESS_486612]. 
Moreover, activation of SYK leads to the release of various inflammatory mediators and plays a 
role in downstream signaling in volved in the pathology of several allergic and autoimmune 
diseases. (14, 17)  Therefore, targeting both JAK and SYK kinases may provide a new therapeutic  
approach in the treatment of inflammatory disorders, such as atopic dermatitis.  
 ASN002 in Atopic Dermatitis  
ASN002 is an orally bioavailable, potent dual inhibitor of JAK and SYK kinases with 50% 
inhibitory concentrations (IC50 values) of 5 -46 nM in biochemical assays. In cell -based 
mechanistic assays, the compound showed inhibition of IgE -immune complex induced 
degranulation and phosphorylation of LAT (Linker for Activation of  T cells) a substrate of SYK, 
and also IL -6 induced phosphorylation of STAT3 (IC50 range 14 –143 nM). In a collagen -
induced arthritis model, ASN002 demonstrated a significant reduction in arthritic, 
histopathology and radiographic scores when compared to ve hicle. The compound also showed 
broad antiproliferative activity in a panel of cell lines representing both solid and 
leukemia/lymphoma tumor types. The data from both in vitro (cell line) and in vivo efficacy 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 26 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  studies with ASN002 provide strong rationale f or its evaluation in subjects with atopic 
dermatitis.  In a Phase 1b study  (ASN002 AD-101), plasma concentrations of ASN002 were 
measured in subjects with at opic dermatitis following single and repeated once daily oral 
administration  at 20, 40 and 80 mg . At steady state, C max and AUC were dose dependent  with 
approximately 1. 5-fold or less accumulation compared to those on Day 1 , and t he m ean 
elimination t 1/2 were 7.3-13.7 hours. At 80 mg, the mean Cmax and AUC tau of ASN002 at steady 
state were 252 ng/ml and 3340 ng*hr/ml , respectively.   The safety and tolerability profile of 
ASN002 at all dose levels was excellent. The most common adverse event (AE) observed was 
transient, mild headache, mostly restricted to Day [ADDRESS_486613] clinical efficacy with nearly all  patients obtaining a 50% 
improvement  in disease  severity (EASI 50) at 40 mg and 80 mg once daily and substantial 
decreases in patient-reported itch measured by [CONTACT_388137]  (NRS)  after 4 weeks of 
treatment.  
 Study Rational e  
In the previous clinical trial (ASN002 AD-101), ASN002 has showed significant be nefit for the 
treatment of atopic dermatitis , especially at [ADDRESS_486614] but not all patients. Additionally, 
they do not prevent or eradicate the disease. The development of medications that precisely target 
the molecular mediators of inflammation involved in AD is certa inly a promising approach to treat 
this disease. There is definitely a need for new treatments in AD in order to increase the existing 
options available to clinicians.  
 
The primary objective of this study is to assess the efficacy of ASN002 in subjects with moderate -
to-severe atopic dermatitis. Safety and tolerability of ASN002 will also be evaluated as secondary 
endpoint as well as its pharmacokinetic profile. The doses to be administered in this study range 
between 40 and 80 mg, which were found to be well tolerated and safe in a previous Phase I study. 
Adverse events (AEs) observed in the Phase I study were of mild or moderate intensity following 
80 mg dose.  One SAE wa s reported (anxiety attack) , which was not related to the study drug,  and 
one event led to treatment discontinuation for one subject (hypertension) in the 80 -mg cohort  (refer 
to section 2.2.1  for more details) . Once daily administration was chosen based on the data from 
the clinical studies in oncology subjects and healthy volunteers.  Pharmacokinetic analyses indicate 
sufficient systemic exposure for ASN002 efficacy  and a half -life of ~10 hours is adequate  for 
maintaining target trough concentrations . 
2.2  Risk/Benefit Assessment  
 Known Potential Risks  
The data from both nonclinical and clinical studies with ASN002 suggest that it is safe and well -
tolerated at the doses to be administered in the present study.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 27 of 76  
Protocol version 3.0: [ADDRESS_486615] dosed with 50 mg ASN002 once. 
These resolved over 5 days without sequelae. This event was considered possibly related to study 
medication and unexpected.  
 
The safety of ASN002 was also assessed in a previous Phase I study in AD patients. Adverse 
events (AEs) observed in the Phase I study were mild or moderate at doses up to 80 mg.  There 
were  no drug -related SAEs reported in this study. One SAE was reported (anxiety attack) , which 
was not related to the study drug . In addition,  one event led to treatment discontinuation for one 
subject (hypertension) in the [ADDRESS_486616] a 
positive benefit/risk ratio for the treatment of atopic dermatitis with ASN002 , and therefore to 
initiate this study.  
 
The risk to subjects in this trial will be minimized by [CONTACT_178438], proper 
study design, and close monitoring.  
 
  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 30 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  4 STUDY DESIGN  
4.1  Overall Design  
This study will be performed at approximately 50 study centers located in the [LOCATION_002] , 
Canada  and [LOCATION_013] . 
 
This study is a randomized, double -blind, placebo -controlled , multicenter, Phase 2 b study . 
Approximately 220 subjects with moderate to severe AD (as defined by a BSA involved with AD 
of ≥ 10%, an EASI ≥ 16, and an IGA ≥ 3  at Day 1 ) will be included  in this study  to complete the 
study with at least [ADDRESS_486617] should read and sign an informed consent form prior to any screening procedures 
being performed. Subjects who fulfill all of the inclusion criteria and none of the exclusion cri teria 
will be accepted into the study. After a screening period of no more than 30 days (from Day -30 
to Day  -1), eligible subjects  will be randomized (1:1 :1:1) on Day 1  to receive ASN002 at 40 mg, 
60 mg, or 80 mg, or placebo once daily for 12 weeks. The treatment period will be followed by a 
4-week follow -up period for subjects not participating in the open label extension (OLE)  study .  
For scheduled study visits, subjects will come to the study centers on seven occasions: screening , 
Day 1, Weeks 2, 4, 8, and 12, and Week 16/  ET for subjects not participating in the OLE study.  
 
Efficacy will be assessed by [CONTACT_78442], EASI, SCORAD, BSA, pruritus NRS  (daily) , and [ADDRESS_486618] -dose PK blood samples will be collected from all subjects on a sparse sampling 
schedule at Day 1, and Weeks 2, 4, 8 and 12  (or ET visit, if applicable) . 
 
At selected study centers, in a subset of approximately 68 subjects who consent, PD blood samples 
will be collected pre-dose on Day 1  and Week 12  (or ET visit, if applicable) . PD samples will be 
obtained from the same subjects who consent to biopsy collection.  An additional PD blood sample 
will be collected at Week 4 in subjects who also consent to four skin biopsies.  
 
At selected study centers, in a subset of approximately 68 subjects who consent , three or four skin 
biopsies will be collected during this study. Two 4.5 -mm punch biopsies (one from lesional skin 
and one from adjacent nonlesional skin) will be c ollected at Day  1, and one 4.5 -mm punch biopsy 
will be collected from the same lesional skin (outside the scar of the previous biopsy , at least [ADDRESS_486619] from the previous scar ) at Week 12 (or ET visit , if applicable). In addition, one 4.5 -mm 
punch biopsy will be collected from the same lesional skin (outside the scar of the previous biopsy , 
at least [ADDRESS_486620] from the previous scar ) at Week 4 in subjects who consent to four skin biopsies.  
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 31 of 76  
Protocol version 3.0: [ADDRESS_486621] (DSMB) during the study.  
4.[ADDRESS_486622] Treatment 
Interruption/Discontinuation  
In the event of an adverse event or laboratory abnormality, individual subject study treatment may 
be temporary or permanently discontinued based on the Investigator’s judgement in accordance 
with the guidelines described in this section.  
 
Treatment may b e resumed upon recovery to baseline or mild levels after the condition leading to 
suspension of dosing resolves, at the  discretion of the principal investigator [INVESTIGATOR_388120].   A decision to temporarily discontinue study drug and /or to reinstitute study 
treatment should be discussed with  the medical monitor.   The investigator may suspend study 
treatment at any time, even without consultation with the medical monitor if the urgency of the 
situation requires immediate action  and if this is determined to be in the subject ’s best 
interest.  However, the medical monitor should be contact[CONTACT_388138]/interruption.   Resumption of study treatment after temporary 
discontinuation should alw ays be discussed with the medical monitor.  
 
Any retreatment should only be considered upon written agreement between the investigator and 
the sponsor. This information pertaining to discontinuation or interruption of study medication and 
the reasons for it  must be recorded in the case report form.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 32 of 76  
Protocol version 3.0: [ADDRESS_486623] the study drug interrupted until 
laboratory retesting is performed and/or event resolution .  
 
• neutrophils > 0.5 x 103 /μL but < 1 x 103 /μL; 
• platelet  count  > 50 x 103 /μL but < 100 x 103 /μL; 
• lymphocytes < 0.5 x 103 /μL but > 0.2 x 103 /μL; 
• CPK >[ADDRESS_486624] ; 
• an infection requiring IV treatment with antiviral, antibiotic, antiprotozoal, antiparasite or 
requiring oral medications of those longer than 2 weeks ; 
• AST/ALT > [ADDRESS_486625] *. 
 
*Decision to restart the medication following  any laboratory  abnormalit y described a bove will 
be made in consultation with the study sponsor and medical monitor . 
 Permanent study discontinuation  
Adverse events or laboratory abnormalities  who meet either of the below criteria will result in 
permanent study discontinuation  of the subject . Treatment with the study product will be 
immediately stopped  and the subject withdrawn from this study.  
 
• serious opportunistic infection such as tuberculosis ;  
• hypertension that cannot be controlled with additional antihypertensive medication (s); 
• neutrophils ≤ 0.5 x 103 /μL; 
• lymphocytes ≤ 0.2 x 103 /μL; 
• platelets ≤ 50 x 103 /μL; 
• diagnosis of malignancy ; 
• venous thrombo -embolic event or major cardiovascular event . 
4.[ADDRESS_486626] three times during the study to assess unblinded 
safet y data on each arm of the study and will provide their recommendations concerning the 
continuation, modification, or termination of the trial.  
 
  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 33 of 76  
Protocol version 3.0: [ADDRESS_486627] mee t all of the following criteria 
at the screening and Day 1 visits, unless specified otherwise :  
1. Male or female subject, aged [ADDRESS_486628] has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and 
Rajka criteria ( Appendix A ). 
3. Subject has at least a 6-month history of atopic dermatitis and had no significant flares in atopic 
dermatitis for at least 4 weeks before screening (information obtained from medical chart or 
subject’s physician, or directly from the subject).  
4. Subject has an EASI score ≥ [ADDRESS_486629] has moderate to severe atopic dermatitis at Day 1, as defined by [CONTACT_388133] ≥  3. 
6. Subject has atopic dermatitis covering ≥ 10% of the BSA on Day 1. 
7. Subject has a body mass index (BMI) ≤ 3 8 kg/m2. 
8. Subject has a history of inadequate response to to pi[INVESTIGATOR_388121] 1 year before the screening visit (information obtained from 
medical chart or subject history).  
9. Subject has been using an emollient (except those containing urea) either once daily or twice 
daily for at least 1  week prior to Day 1  and agrees to continue using that same emollient, daily 
and at the same frequency, throughout the study.  Note: On the day of scheduled visits, subjects  
cannot  apply emollient before their scheduled visit time.    
10. For women  of childbearing potential involved in any sexual intercourse that could lead to 
pregnancy : the subject must agree to use a highly effective contraceptive method from at least 
[ADDRESS_486630] administration. Highly 
effective contraceptive methods include hormonal contraceptives (combined oral 
contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine 
systems, vasectomized partner(s), tubal ligation, or double barrier method s of contraception  
(barrier methods include male condom, female condom, cervical cap, diaphragm, and 
contraceptive spong e) in conjunction with spermicide.  
Note: Subjects must have been on a stable dose of hormonal contraceptives for at least 4 weeks 
before Day  1.  
Note: The above list of contraceptive methods does not apply to subjects who are abstinent for 
at least 4 week s before Day 1 and will continue to be abstinent from penile -vaginal intercourse 
throughout the study.  The reliability of sexual abstinence needs to be evaluated in relation to 
the duration of the clinical trial and the preferred and usual lifestyle of th e participant.  
Note: For countries where double barrier methods are not accepted as highly  effective 
contraception, then this option must not be considered.  
Note: A woman of nonchildbearing potential is as follows:  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 34 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  a. Woman  who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or 
bilateral salpi[INVESTIGATOR_1656]);  
b. Woman who has had a cessation of menses for at least 12 months without an 
alternative medical cause, a nd a follicle -stimulating hormone (FSH) test confirming 
nonchildbearing potential (refer to laboratory reference ranges for confirmatory 
levels).  
11. For men involved in any sexual intercourse that could lead to pregnancy, subject must 
agree to use one of the  highly effective contraceptive methods listed in Inclusion 
Criterion  #10, from Day  [ADDRESS_486631] is willing to participate and is capable of giving informed consent. Note: Consent 
must be obtained prior to any study -related procedures.  
14. Subjects must be willing to comply with all study procedures and must b e available for the 
duration of the study.  
5.[ADDRESS_486632] who meets any of the following criteria at the screening and Day  1 visits, unless specified 
otherwise, will be excluded from participation in this study:  
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant 
during the study.  
2. Subject has clinically infected atopic dermatitis.  
3. Subject has a history of skin disease or presence of skin condition that, in the opi[INVESTIGATOR_1070], would interfere with the study assessments.  
4. Active infection, including skin in fection, requiring treatment.  
5. Subject has a history of  cancer or lymphoproliferative disease within 5 years prior to Day  1. 
Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell 
carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.  
6. Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs 
abnormality that would, in the opi[INVESTIGATOR_871], put the subject at undue risk or 
interfere with interpretation of study results.  
7. Subject has 12 -lead ECG abnormaliti es considered by [CONTACT_388139] F ≥ 450 milliseconds, regardless of clinical significance, at screening. 
Abnormal ECG may be confirmed with one repeat assessment. For subjects with QTcF≥[ADDRESS_486633] has a history of congestive heart failure [LOCATION_001] Heart Association (NYHA) class 
III or IV.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 35 of 76  
Protocol version 3.0: [ADDRESS_486634] has a history of erythrodermic, refractory or unstable skin disease, including AD, that 
requires frequent hospi[INVESTIGATOR_4355]/or intravenous treatment for skin infections  over the last 
year 
10. Subject has a history of eczema herpeticum within 12 months, and/or a history of [ADDRESS_486635] has a histo ry of recurrent venous thromboembolic event (VTE) (>=2)  
12. Subject has experienced any of the following within the last 6 months prior to Day 1: VTE 
myocardial infarction, angioplasty, or cardiac stent placement, unstable ischemic heart disease, 
or stroke.  
13. Subject had other major surgery within [ADDRESS_486636] has positive results for hepatitis B surface antigens (HBsAg), antibodi es to hepatitis B 
core antigens (anti -HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) 
at the screening visit.  
16. Presence of any of the following laboratory abnormalities at the screening visit:  
a. Hemoglobin < 11 g/dL;  
b. White blood cell (WBC) < 3.0 x 103 /μL; 
c. Platelet count < 125 x 103 /μL; 
d. Neutrophils < 1.8 x 103 /μL; 
e. Lymphocytes < 1.0 x 103 /μL; 
f. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x the upper 
limit of normal (ULN).  
g. Total bilirubin > 1.[ADDRESS_486637] (except for elevated indirect bilirubin secondary to 
Gilbert’s syndrome);  
h. Creatinine > ULN.  
17. Subjects has uncontrolled hypertension within the last 1 month prior to screening or blood 
pressure at screening of systolic blood pressure > 160 mm Hg or diastolic BP >[ADDRESS_486638] has a known active tuberculosis or a positive tuberculosis (TB) infection test.  Subject 
will be evaluated for latent TB infection with a purified protein derivative ([COMPANY_003]) test or a 
QuantiFERON -TB Go ld test. Subjects who demonstrate evidence of latent TB infection (either 
[COMPANY_003] ≥[ADDRESS_486639], irrespective of bacille 
Calmette -Guérin vaccination status) will only be allowed to participate in the study if there is  
documented evidence of a completed adequate treatment course for latent TB (with negative 
chest x -ray findings for active TB).  
19. Subject has difficulty swallowing medications, or known history of malabsorption syndrome.  
20. Subject has a history of recurrent gastroesophageal reflux disease (GERD) requiring the use of 
proton pump inhibitors within the last month.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 36 of 76  
Protocol version 3.0: [ADDRESS_486640] has uncontrolled diabetes.  
23. Any medical or psychiatric condition which, in the opi[INVESTIGATOR_388122]’s 
medical monitor, would place the subject at risk, interfere with participation in the study, or 
interfere with the interpretation of study results.  
24. Subject has used dupi[INVESTIGATOR_207928] [ADDRESS_486641] has received any UV -B phototherapy (including tanning beds) or excimer laser within 
[ADDRESS_486642] has had psoralen -UV-A (PUVA) treatment within [ADDRESS_486643] has used systemic treatments (other than biologics) that could affect atopic dermatitis 
less than 4 weeks prior to Day 1 (e.g., retinoids, calcineurin inhibitors, methotrexate, 
cyclosporine, hydroxycarb amide [hydroxyurea], azathioprine, oral/injectable corticosteroids). 
Note: Intranasal corticosteroids, eye drops containing corticosteroids, and inhaled 
corticosteroids for stable medical conditions are allowed.  
33. Subject has received any marketed or invest igational biological agent within 12 weeks or 5 
half-lives (whichever is longer) prior to Day 1.  
34. Subject is currently receiving any other medication for AD . 
35. Subject is currently receiving a nonbiological investigational product or device or has received 
one within [ADDRESS_486644] has received a live attenuated vaccine within 4 weeks prior to Day 1 or plans to receive 
a live attenuated vaccine during the study and up t o 4 weeks or 5 half -lives (of the study 
product), whichever is longer, after the last study product administration.  
38. Subject has used ASN002.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 37 of 76  
Protocol version 3.0: [ADDRESS_486645] has a close affiliation with the investigator (e.g., a close relative) including any study 
staff of the sites or persons working at the CRO or subject is an employee of the sponsor.  
43. Subject is institutionalized because of legal or regulatory order.  
44. Only f or subjects consenting to biopsies:  
a. Subject has a history of an allergic reaction or significant sensitivity to lidocaine or 
other local anesthetics;  
b. Subject has a history of hypertrophic scarri ng or keloid formation in scars or suture 
sites;  
c. Subject is taking anticoagulant medication, such as heparin, low molecular weight 
(LMW) -heparin, warfarin, antiplatelets (except low -dose aspi[INVESTIGATOR_388123]), within 2 weeks prior to Day 1,  or has  a contraindication to skin biopsies. 
Nonsteroidal anti -inflammatory drugs [NSAIDs] will not be considered antiplatelets 
and will be allowed.  
5.[ADDRESS_486646] ’s withdrawal should be made with an 
explanation of why the subject  is withdrawing from the study. If the reason for removal of a subject  
is an AE or an abnormal laboratory test result, the principal specific event or test will be recorded.   
 
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this written request in the site study records.  
 Discontinuation  
Subjects who discontinue the study after the first dose will be asked, if they agree, to come for a 
last assessment ( ET visit) . Subjects who receive an active treatment for AD after Week 4 visit are 
not necessarily discontinued from the study (refer to section 6.4.2  for more information on how to 
proceed with these subjects) . Subjects who have their study product discontinued due to the start 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 38 of 76  
Protocol version 3.0: [ADDRESS_486647] discontinuation 
(in addition to the ET visit).  
 
Subjects who did not complete the study for reasons other than safety, or have demonstrated 
significant noncompliance to study treatments  based on IP accountability (define as subject who 
received <80% or >120% of the scheduled doses during the study treatment period)  will be 
evaluated by [CONTACT_458] [INVESTIGATOR_388124]. 
If a subject drops out during the first [ADDRESS_486648] may be replaced  at sponsor’s 
discretion .  
 
Reas ons for discontinuation include  the following : 
• The investigator decides that the subject  should be withdrawn. If this decision is made because 
of a serious adverse event  (SAE) , the study product is to be discontinued in that subject 
immediately and appropriate measures are to be taken. The investigator will notify the sponsor 
immediately . 
• The attending physician requests that the subject  be withdrawn from the study . 
• The subject, for any reason, requires treatment with another therapeutic agent  may be 
discontinued as detailed in section 6.4.2 .  
• The subject  is lost to follow -up. In this case, a reasonable attempt to contact [CONTACT_388140] , and these attempts must be documented . 
• The subject become s pregnan t at any time during the study .  
• The subject  may withdraw from the study for any other reason, including withdrawal of 
consent.  
• The sponsor or regulatory authorities, for any reason, stop the study. In this case, all subjects 
will be discontinued from the study. The investigator will immediately, on  discontinuance of 
the study by [CONTACT_456], in its entirety or at a clinical trial site, inform both the subjects and 
the research ethics board of the discontinuance, provide them with the reasons for the 
discontinuance and advise them in writing of any p otential risks to the health of subjects or 
other persons.  
 Lost to Follow -Up 
A subject will be considered lost to follow -up if he or she fails to return for scheduled visits and is 
unable to be contact[CONTACT_136589].  
 
The following actions mus t be taken if a subject  fails to return to the clinic for a required study 
visit:  
• The site will attempt to contact [CONTACT_75359]. The site will 
then counsel the subject on the importance of maintaining the assigned visit schedule and 
ascertain if the subject wishes to or should continue in the study.  
• Before a subject is deemed lost to follow -up, the investigator or designee will make every 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 39 of 76  
Protocol version 3.0: [ADDRESS_486649] (where possible, three telephone calls and , if 
necessary, a certified letter to the subject’s last known mailing address or local equivalent 
methods). These contact [CONTACT_9300]’s medical record or 
study file.  
• If all attempts to contact [CONTACT_18356], he or she will be considered to have withdrawn 
from the study with a primary reason of lost to follow -up. 
5.4  Screen Failures  
Screen failures are defined as individuals who consent to participate in the clinical trial, but are 
not subsequently randomly assigned to the study products . A minimal set of screen failure 
information is required to ensure transparent reporting of screen  failure subjects, to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and to respond 
to queries from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, and a ny SAEs.  
 
Individuals who do not meet the criteria for participation in this trial (screen failure) may be 
rescreened once, if deemed acceptable by [CONTACT_093]. Rescreened subjects should be assigned 
a different subject number than the initial screeni ng. All procedures planned at the screening visit, 
including signature [CONTACT_4007] a new consent form, will be performed.  
 
Subjects who do not qualify to participate in the study due to a screening laboratory value 
abnormality can repeat the test once within the or iginal screening time window without resulting 
in screen failure, if the investigator believes there is a reasonable possibility that the subject would 
be eligible if re -tested.  
  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 41 of 76  
Protocol version 3.0: [ADDRESS_486650] is 12 weeks.  
6.2  Preparation/Handling/Storage/Accountability  
 Preparation /Storage/Handling   
All study products must be stored in a secure environmentally controlled and monitored area in 
accordance with the labelled storage conditions with access limited to the investigator and 
authorized site staff.  The study product(s)  may only be supplied by [CONTACT_388141].   
 
Study product (s) will be dispensed by [CONTACT_388142] 1. Subjects are to return all study product (used and unused) to the study site. The tablets  
will be counted prior to dispensing and upon return , and the counts will be recorded in the source 
documents. Each subject will be instructed on the importance of returning study product at the next 
study visit  and on taking the product as prescribed . If a subject does not return study product , he 
or she wi ll be instructed to return it as soon as possible . 
 Accountability  
The investigator is responsible for maintaining accurate records of the study product received 
initially  and of  the study product dispensed/used . After verification of the study product 
accountability by [CONTACT_36613], used product will be stored safely until 
destruction/return. Any study product accidentally or deliberately destroyed, or returned to the 
sponsor or designee will be account ed for. Any discrepancies between amounts dispensed and 
returned will be explained.  
 
All study product accountability forms and treatment logs must be retained in the investigator’s 
study file s. Product  inventory and accountability records will be maintain ed as per ICH GCP . 
These records must be available for inspection at any time by [CONTACT_456] , its designees , or by 
[CONTACT_17513].  
 
Further guidance and information for final disposition of study products  are provided in the study 
manual .  
6.[ADDRESS_486651] number  and will be assigned in numerical order at the 
screening visit based on chronological order of screening dates (e.g., 002-[ADDRESS_486652] 
screened at the Site # 002). 
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 42 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  Approximately 220 subjects will be randomized in a 1:1:1:[ADDRESS_486653] w ill be 
generate d using a validated software. Randomization will be stratified by [CONTACT_388143] 1 ([EASI = 16.0-21.2] vs. [EASI = 21.3-29.9] vs. [EASI = ≥ 30.0]) and biopsy collection . 
The master  randomization list will be kept secured until the study blind is broken  at the end of 
study . This list will be upload ed into an Interactive Web Response  System  (IWR S). The 
investigator or designee will be able to acquire a randomization number  for eligibl e subjects by 
[CONTACT_388144] . 
 
Further guidance and information can be obtained in the study manual . 
 Blinding 
This study will be double -blinded. At all times, treatment and randomization information will be 
kept confidential and will not be released to the investigator, the study staff, the contract research 
organization ( CRO ), or the sponsor’s study team until after the conclusion of the study.   
 
Safety oversight will be under the direction of a n independent  DSMB , who will remain unblinded 
during the study .  
 
Blinding codes should only be broken in emergency situations for reasons of subject safety. If 
unblinding the treatment assignment for a subject  is necessary due to a medical emergency (an 
unexpected SAE per product’s safety profile)  and other significant medical situations such as 
pregnancy , the investigator can make the decision to unblind the treatment assignment if knowing 
the treatment assignment will help treatment decision of the particular AE. When the blind for a 
subject has been broken, the reason  must be fully documented  in the source document and eCRF . 
Whenever possible, the investigator should contact [CONTACT_388145]. If the blind is broken, the investigator should promptly inform the medical monitor.  
Docume ntation of breaking the blind should be recorded with the date /time  and reason why the 
blind was broken, and the names of the personnel involved.  
 
Emergency u nblinding  details are provided in the study manual.  
 
The subject for whom the blind has been broke n will be discontinued from the study and undergo 
the ET procedures . In cases where there are ethical reasons to have the subject remain in the study, 
the investigator must obtain specific approval from the sponsor or its designee for the subject to 
continue in the study.  The primary reason for discontinuation (the event or condition which led to 
the unblinding) will be recorded.  
 Study Product  Compliance  
Study product  compliance will be monitored  at each visit. Adherence to treatment  will be assessed 
by [CONTACT_81257], review of the subject ’s dosing diary , and by [CONTACT_388146] , LLC– Protocol ASN002AD -201 Page 43 of 76  
Protocol version 3.0: [ADDRESS_486654]  in the 
same time frame, as judged by [CONTACT_093].  
6.4  Concomitant Therapy  
All medications (including over -the-counte r drugs, vitamins, herbal/natural products and antacids) 
taken within [ADDRESS_486655] be recorded.  
 
Medication entries may be captured as generic  or trade  name s. Trade name s should be used for 
combination drugs. Entries should include as much as possible of the following information: the 
dose, unit, frequency of administration, route of administration, start date, discontinuation date, 
and indication. If the medication is discontinue d or the dosage  is changed, these details must be 
recorded.  
 Permitted Therapi[INVESTIGATOR_388125] (except those containing urea) on their skin. The 
emollient use must be initiated at least [ADDRESS_486656]  be kept at the same 
frequency (once or twice daily) throughout the study until the follow -up visit at Week 16. 
However, on the day of scheduled visits, subjects cannot  apply emollient before their scheduled 
visit time.    
 
Every effort should be made to keep the same emollient throughout the study. The commercial 
name [CONTACT_388167](s) will be recorded in the source document and the eCRF. No other 
products may be applied to the lesions during the study.  Emollient use will be followed daily in 
the subject diary.  
Use of sunscreen products  and protective apparel are permitted when exposure cannot be avoided.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 44 of 76  
Protocol version 3.0: [ADDRESS_486657] study visit .  
 
The discretionary use of concomitant treatments or therapi[INVESTIGATOR_388126] 1 and Week 16 visit.  However, should subjects experience an exacerbation of atopic 
dermatitis that requires, in the opi[INVESTIGATOR_871], the use of a prohibited therapy , the 
following approach should be followed :   
 
1. The investigator needs to discuss the case with the medical monitor in order to obtain 
permission to use a prohibited medication.  
2. Subjects who start prohibited medications as a treatment for AD within the first [ADDRESS_486658] (ASN002 or placebo)  and will 
perform the ET visit at the time of discontinuation. In addition, the subject will be asked to 
come back for a follow -up visit [ADDRESS_486659] (ASN002 or placebo). 
Use of oral corticosteroids  after permanent cessation of ASN002  is permitted only for a 
short period of time (maximum 3 weeks). Subjects should come to all planned study visits 
for safety assessments up to the Week [ADDRESS_486660] (ASN002 or 
placebo)  and will perform the ET visit at the time of discontinuation . In addition, the 
subject will be asked to come back for a follow -up visit [ADDRESS_486661] is 
stopped.  Collection of PD samples, PK samples, and skin biopsies will not be pe rformed 
after the ET visit.  These subjects may be eligible to participate in the OLE study  not earlier 
than 12 weeks after Day 1 of the present study and only  if they meet the required washout 
period for prohibited systemic medications as defined in the OL E study.    
6. Subjects who start any other prohibited medications or therapi[INVESTIGATOR_388127], at the investigator’s discretion  in agreement with the medical 
monitor and the sponsor . 
 
If in any doubt, investigators are advised to discuss medications with the medical monitor.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 47 of 76  
Protocol version 3.0: [ADDRESS_486662] (board certified or equivalent)  or other suitably qualified and experienced designee . 
To assure consistency and reduce variability, the same  assessor should perform all assessments on 
a given subject whenever possible . 
 Eczema Area and Severity Index  
The Eczema Area and Severity Index (EASI) will be assessed at the visits specified in  Table  [ADDRESS_486663]’s atopic dermatitis 
based on both lesion severity and the percent age of BSA affected  (18). The EASI is a composite 
score ranging from 0  to 72 that takes into account the degree of erythema, induration/ infiltration 
(papul es), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four 
body regions, with adjustment for the percent age of BSA involved for each body region and f or 
the proportion of the body region to the whole body. A detailed procedure of EASI score 
calculation is provided in Appendix B . To be eligible for this study, subjects must have an EASI 
score of ≥ 16 at Day  1. 
 Investigator Global Assessment  
The Investigator Global Assessment (IGA) of disease severity will be assessed at t he visits 
specified in  Table [ADDRESS_486664] an IGA score of ≥ 3 at Day  1. 
 SCORing Atopic Dermatitis  
The SCORing Atopic Dermatitis  (SCORAD ) will be measured at the visits specified in  Table [ADDRESS_486665] administration . The SCORAD grading system was developed by [CONTACT_388147] (1993) and has been a standard tool to assess AD 
severity in c linical studies in Europe (19, 20) . Six items (erythema, edema/papulation, 
oozing/crusts, excoriation, lichenification, and dryness) will be evaluate d the AD severity. The 
overall BSA affected by [CONTACT_388148] (from 0 % to 100%) and included in the SCORAD 
scores. Loss of sleep and pruritus will be evaluated by [CONTACT_388149] a visual analog scale (0 -10) and 
should be based on the average of the last three days/nights . The sum of these measures represents 
the SCORAD , which can range  from 0 to 103. The detailed procedure of SCORAD score 
calculation is provided in Appendix D .  
 Body Surface Area  
The overall Body Surface Area ( BSA ) affect ed by [CONTACT_388148] (from 0 % to 100%) at the 
visits specified in Table [ADDRESS_486666] ’s palm represents 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 49 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  
  Dermatology Life Quality Index Questionnaire  
The Dermatology Life Quality Index (DLQI ) will be assessed at the visits specified in Table  1. It 
is a simple [ADDRESS_486667] 5 minutes: systolic and diastolic blood pressure 
(mmHg), pulse (bpm), and body temperature (°C) . 
 
Weight (kg) and height (cm) will be collected to calculate the BMI and  will be recorded at the 
visits  specified in Table 1. The height will only be recorded at the screening visit and the same 
value will be used for BMI calculation at other visits.  
 
If deemed appropriate by [CONTACT_093], clinically significant findings in the vital signs will 
exclude a subject from study participation. Any abnormal finding related to vital signs that the 
investigator considers to be clinically significant must be recorded as an AE . 
 Physical Examination  
The following sites/systems will at least be included in the physical examination , which will be 
performed at the visits specified in Table  1:  
 
• General appearance  
• Dermatological (except atopic dermatitis ) 
• Head, eyes, ears, nose, throat (HEENT)  
• Respi[INVESTIGATOR_696]  
• Cardiovascular  
• Abdominal  
• Neurological  
• Musculoskeletal  
• Lymphatic  
Information for all physical examinations must be included in the source document.  If deemed 
appropriate by [CONTACT_093], clinically significant findings in the physical examination will 
exclude a subje ct from study participation. Any significant change will be reported as an AE in 
the source document and eCRF . 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 50 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Brief Physical Examination  
The following sites/systems will at least be included in the brief physical examination that will be 
performed at the visits specified in Table  1:  
 
• General appearance  
• Dermatological (except atopic dermatitis ) 
• Respi[INVESTIGATOR_696]  
• Cardiovascular  
• Abdominal  
 
Information for all physical examinations must be included in the source document. If deemed 
appropriate by [CONTACT_093], clinically significant findings in the physical examination will 
exclude a subject from study participation. Any significant change will be reported as an AE in 
the source document and eCRF .  
 Clinical Laboratory Tests 
Laboratory tests will be performed at the visits specified in Table  1. The tests will include 
urinalysis, hematology with differential, a standard chemistry panel (chemistry includes liver 
function tests and chole sterol),  and serum pregnancy test (screening) for women of childbearing 
potential (WOCBP). At the visit specified in Table  1, a urine pregnancy test will be performed for 
WOCBP (conducted at the investigator site). The specific tests in these panels are listed in  
Table 5. 
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 52 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  7.4 Phar macokinetic and Pharmacodynamic Assessment s 
 Pharmacokinetics  Assessment s  
Blood samples will be collected for PK assessment  on visits and time points indicated in the 
schedule of events in Table  1. Measurement of plasma concentrations of ASN002 will be 
performed in all subjects receiving ASN002 treatment. A few samples from each of the placebo 
subjects (e.g., pre -dose on Day 1 and 2 hour s at Week 4) may be analyzed for quality control  
purposes . 
 
The actual date and time of each blood sample collection will be recorded . Approximately [ADDRESS_486668]  administration. 
PD samples will be obtained from the same subjects who consent to biopsy collection.  
 
The actual date and time of each blood sample collection will be recorded. Approxi mately 8 mL 
of blood will be collected for each time point.  
 
Details about the collection, processing, handling, storage and shippi[INVESTIGATOR_388128].  
 PK/PD Relationship Assessment s  
PK-efficacy, PK -safety and PK -biomarkers relationships will be explored using linear regression, 
loess plots, Hills functions, or logistic regression, as appropriate. The results from these analyses 
may be reported separately.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 53 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Skin Biopsies  
At selected study centers, f or a subset of approximately 68 subjects who consent to the procedure,  
three or four optional skin biopsies will be collected at the visits specified in Table 1. Two 4.5 -mm 
punch biopsies (one from lesional skin and one from adjacent nonlesional skin) will be collected 
at Day  1, and one 4.5 -mm punch biopsy will be collected from the same lesional ski n (outside the 
scar of the previous biopsy , at least [ADDRESS_486669] from the previous scar ) at Week 12 or ET visit (if 
applicable). In addition, one 4.5 -mm punch biopsy will be collected from the same lesional skin 
(outside the scar of the previous biopsy , at least [ADDRESS_486670] from the previous scar ) at Week [ADDRESS_486671] eczema involvement will be taken to illustrate any visible clinical change. A target area 
for each participant will be identified at Day 1, and the same area  will be photographed at the other 
visits.  Care will be taken to use the same camera, the same magnification, and the same settings 
for each photograph at each visit in order to obtain comparable pi[INVESTIGATOR_499] . Medical photographs  will 
be taken using a blue ba ckground .  
 
Photographs will be identified and stored  as instructed in  the photography  manual.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 54 of 76  
Protocol version 3.0: [ADDRESS_486672] a causal relationship with this treatment. An AE can therefore 
be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the u se of a study product, whether or not considered related to 
the study product.  AEs and SAEs will be c ollected from the time of informed consent signature 
[CONTACT_388168] / contact.  
 Definition of Treatment -Emergent Adverse Event  
A TEAE is any conditio n that was not present prior to treatment with the study product but 
appeared following treatment, was present at treatment initiation but worsened during treatment, 
or was present at treatment initiation but resolved and then reappeared while the individu al was on 
treatment (regardless of the intensity of the AE when the treatment was initiated).  
 Definition of Serious Adverse Event  
A serious adverse event or reaction is any untoward medical occurrence that, at any dose has any 
of the following consequences:  
• Results in death  
• Is life -threatening  
• Requires in -patient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
Note: The term “life -threaten ing” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically 
might have caused death if it were more severe.  
Medical and scientific judgment sho uld be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately life -
threatening or result in death or hospi[INVESTIGATOR_059], but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above.  These should also 
usually be considered serious . 
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059]; or 
development of drug dependency or drug abuse.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 55 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Classification of an Adverse Event  
[IP_ADDRESS]  Relationship to Study Product  
 
The investigator will establish causality of the AE to the experimental tre atment. The investigator 
should take into account the subject’s history, most recent physical examination findings, and 
concomitant medications.  
The degree of “relatedness” of the AE to the study medication must be described using the 
following scale:  
Not related indicates that there is not a reasonable possibility for relationship of the event to 
the study medication.   
Possibly related indicates that a direct cause and effect relationship between study medication 
and the AE has not been demonstrated, but  there is evidence to suggest there is a reasonable 
possibility that the event was caused by [CONTACT_7860].  
Probably related  indicates that there is evidence suggesting a direct cause and effect 
relationship between the AE and the study medication.  
 
The statement " reasonable possibility for relationship " meaning that there are facts (e .g., 
evidence such as de -challenge/re -challenge/temporal relationship, exposure, likely cause due to 
known safety profile etc) to suggest a positive causal relationship. The investigators may also 
change their opi[INVESTIGATOR_388129] -up information  and may provide a follow -up SAE 
report with the revised causality assessment.  
 
[IP_ADDRESS]  Adverse Event Severity  
 
The intensity of an AE is an estimate of the relative severity of the event made by [CONTACT_388150]. The following definitions 
are to be used to rate the severity of an AE:  
• Mild: The symptom is barely noticeable to the subject and does not influence performance 
of daily activities. Treatment is not ordinarily indicated.  
• Moderate:  The symptom is sufficiently severe to make the subject uncomfortable, and 
performance of daily activities is influenced. Treatment may be necessary.  
• Severe: The symptom causes severe discomfort, and daily activities are significantly 
impaired or prevented . Treatment may be necessary.  
[IP_ADDRESS]  Expectedness  
 
The expectedness of each SAE in relation to the study product  will be determined , in consultation 
with the Sponsor when necessary.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 56 of 76  
Protocol version 3.0: [ADDRESS_486673] presenting for medical care, or upon review by a study monitor.  
 
All AEs, including local and systemic reactions, will be captured on the appropri ate eCRF. 
Information to be collected includes event description, date of onset, clinician’s assessment of 
severity, relationship to study product (assessed only by [CONTACT_31278] a diagnosis), and date of resolution/stabiliz ation of the event. All AEs occurring while on 
study must be documented appropriately regardless of relationship.  
 
Before subject enrollment, study site personnel will note the occurrence and nature of each 
subject’s medical condition(s) in the appropriate section of the source document and eCRF. During 
the study, site personnel will note any change in the condition(s)  and the occurrence and nature of 
any AE.  
 
Any medical condition that is present at the time of consent signature  [CONTACT_388169]. However, if the study subject’s condition deteriorates 
after the consent signature , it will be recorded as an AE.  
 
If a subject experiences an AE at any time after the informed conse nt signature  [CONTACT_388170], the event will be recorded as an AE in the source document and eCRF. 
Any SAE related to the study participation (e.g., screening procedure) will be recorded in the 
source document and eCRF from the time a subject consents to participate in the study until the 
end of participation in the study.  
 
The investigator is responsible for appropriate medical care of subjects during the study. The 
investigator also remains responsible for following through wit h an appropriate health care option 
for all AEs that are ongoing at the end of the study. The subject should be followed until the event 
is resolved or stable. If an AE is ongoing at the end of study, the follow -up duration is left to the 
discretion of the  investigator.  Follow -up frequency will be performed at the discretion of the 
investigator .  
 
Whenever possible, clinically significant abnormal laboratory results are to be reported using the 
diagnostic that resulted in the clinically significant abnormal  laboratory results and not the actual 
abnormal test.  
 
Worsening of atopic dermatitis is captured by [CONTACT_388151].   
 Adverse Event Reporting  
Investigators are responsible for monitoring the safety of subjects who a re participating in this 
study and for alerting the sponsor of any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the subject.  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 58 of 76  
Protocol version 3.0: [ADDRESS_486674] complete a 
study -specific pregnancy form upon confirmation of a pregnancy and send it to  within 
24 hours of confirmation of the pregnancy (contact [CONTACT_388152]). will report all cases of pregnancy to the sponsor and CRO in a timely manner. 
Posttreatment follow -up should be done to ensure subject safety. Pr egnancy is not itself an AE or 
SAE; however, maternal/fetal complications or abnormalities will be recorded as AEs or SAEs, as 
appropriate. The investigator will follow the pregnancy until completion or until pregnancy 
termination and, in the case of a liv e-born offspring, to [ADDRESS_486675] treatment assignment may be unblinded if judged 
necessary by [CONTACT_1755]/or medical monitor  in consultation with the sponsor . Once the 
subject treatment assignment is unblinded, the subject for whom the  blind has been broken will be 
discontinued from the study and undergo the ET procedures.  
 Overdose  
Study drug overdose is any accidental or intentional use of study drug in an amount higher than 
the dose indicated per protocol for a given subject. Study dr ug compliance (see section 6.3.2 ) 
should be reviewed to detect potential instances of overdose (intentional or accidental).  
 
Any study drug overdose during the stud y should be recorded  on the source document and eCRF . 
In the event of overdose, the subject should be closely monitored for any potential AEs. All AEs 
associated with an overdose should be entered on the Adverse Event eCRF and reported using the 
procedures detailed in section  7.6.[ADDRESS_486676] still be reported using the SAEs reporting procedures and in an expedited manner, but 
should be noted as non -serious on the form and the Adverse Event eCRF.  The excess quantity and 
duration of the overdose should be recorded.  

Asana BioSciences , LLC– Protocol ASN002AD -201 Page 59 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  8 STATISTICAL CONSIDERATIONS  
8.1  Sample Size  Determination  
Using the following assumptions for the primary efficacy endpoint: a change -from -baseline in 
EASI at week [ADDRESS_486677], we would need 40 evaluable subjects  per group in order to achieve a power of 92%  on 
the primary efficacy endpoint.  
 
Moreover, with [ADDRESS_486678] 80% power to show a statistically 
significant difference between the higher dosing group and placebo in IGA responses (one of the 
key secondary efficacy endpoint), assuming a response of 37.5% vs. 11.1% i n the higher dosing 
and placebo groups, respectively, using an alpha of 5%.   
 
Thus, assuming about 15% dropout rate, [ADDRESS_486679] a minimum of 46 subjects  per gro up to evaluate 
efficacy with adequate power.  
8.2 Populations  for Analyses  
Modified Intent -to-Treat Population (mITT):  This population will include a ll subjects who 
received at least one dose of the study product. All subjects will be analyzed according to the 
treatment group to which they were randomized.  The mITT population will be used as the primary 
analysis population for efficacy.  
 
The Per Protocol Population ( PP): This population will include a ll subjects who were randomized , 
who received  at least one dose of study product, with no significant protocol deviations , and who 
provided evaluable data for the primary endpoi nt. All subjects will be analyzed according to the 
treatment group that they actually received.  
 
The Safety Population  (SAF) : This population will include a ll subjects who received at least one 
dose of the study product . All subjects will be analyzed according to the treatment group that they 
actually received . 
 
The PK Population:  This population will include a ll subjects who received at least one dose of 
ASN002 and have plasma concentration data.  
 
The PD Population:  This population will include all subjects who have at least one assessments of 
PD parameters  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 60 of 76  
Protocol version 3.0: [ADDRESS_486680] deviation, median, minimum, and maximum. Categorical variables will be presented in 
tables as frequencies and percentages.  
 
The primary efficacy analysis will be done using the mITT population and the PP population will 
be used as supportive analysis. All efficacy analyses will be perfo rmed using Mixed Model 
Repeated Measures (MMRM) analyses as primary analyses to take care of missing observations. 
Moreover, the analyses performed  on observed case (i.e. without imputation of missing 
observations) will be done as sensitivity analyses.  
 
Additional  details regarding the efficacy and safety variable definitions, analyses strategy,  control 
of the overall type 1 error, statistical justification, and techniques for handling missing values (e.g. 
for subjects who started prohibited medications) will be detailed in a SAP that will be prepared 
before the databa se is locked and any analyses are  undertaken.  
 Efficacy Analys es 
The primary efficacy endpoint will be analyzed using a repeated measures analysis of covariance 
on change -from -baseline variable to compare the time profile between treatments where the visit 
will be the time factor; and the stratification factors, treatment group, and interaction term for 
treatment -by-visit will be the fixed effects and the baseline va lue will be the covariate. An 
unstructured variance -covariance matrix will be used. Additional interaction terms will also be 
included in supportive statistical models and will be detailed in the SAP.  
 
Sensitivity Analyses:  
 
An analysis of covariance (ANCO VA) will be performed, where the absolute change from baseline 
at Week 12 will be the dependent variable; the treatment group and the stratification factors will 
be the fixed effects; and the baseline value will be the covariate. A supportive analysis with  Site 
and Site -by-Treatment interaction included as fixed factors in addition to the other factors listed 
above will be performed in order to study the impact of site on efficacy.  
 
A similar approach as for the primary endpoint will be done for all other c ontinuous efficacy 
endpoints.  
 
For categorical efficacy endpoints involving proportions of IGA, EASI and NRS (e.g. the 
proportion of subjects achieving at least a 2 -grade reduction from baseline to clear (0) or almost 
clear (1) in Investigator’s Global As sessment (IGA) at week 12), a Cochran Mantel Hansel test 
(CMH) controlling for the stratification variables will be performed.  
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 61 of 76  
Protocol version 3.0: [ADDRESS_486681] (40mg vs. Placebo, 60mg vs. Placebo and 
80mg vs. Placebo) at alpha of 0.0167.  
 Safety Analys es 
All safety da ta, including AEs and SAEs will be presented and tabulated according to  Medical 
Dictionary for Regulatory Activities  (MedDRA ) classification. Descriptions of AEs will include 
the start date , the stop date  (if it resolved), the severity and seriousness of t he AE, the causality of 
the AE to study product , and the outcome. The focus in this protocol will be the prevalence  of 
TEAEs  and drug-related TE AEs. 
 
Reported AEs will be summarized by [CONTACT_178459], as well as by 
[CONTACT_1196], Preferred Term, severity, seriousness, and relationship to study product . For 
the summary of AEs by [CONTACT_926], each subject will be counted onl y once within a System Organ 
Class or a Preferred Term by [CONTACT_388153]. For the summary of AEs by [CONTACT_134345] , each subject will be 
counted only once within a System Organ  Class or a Preferred Term by [CONTACT_388154]. For the summary of AEs by [CONTACT_388155], each subject will be counted only once within a System Organ Class 
or a Preferre d Term by [CONTACT_2329] (1) the greatest reported relationship followed by (2) the highest 
reported intensity.  
 
All information pertaining to AEs noted during the study will be listed by [CONTACT_1130], detailing 
verbatim, System Organ Class, Preferred Term, start date, stop date, intensity, outcome , and 
relationship to study product . The AE onset will also be shown relative (in number of days) to the 
day of study product  administration. SAEs  will be tabulated by [CONTACT_1570], relationship to 
the test article, and a re ference to the occurrence of the SAEs to the relative day of dosing.  
 
Results from laboratory analyses , vital signs , ECGs , and physical examinations  will be tabulated 
by [CONTACT_388156]. The value at each visit as well as t he change 
from baseline will be presented descriptively.  
 
Concomitant medications will be coded with the World Health Organization ( WHO ) Drug 
Dictionary and listed by [CONTACT_1130]. Summary of medication classes will also be tabulated.  
 
No inferential statisti cs will be done on safety variables.  
 Pharmacokinetic Analyses  
ASN002 c oncentration data will be listed per subject and summarized descriptively per dose.  
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 62 of 76  
Protocol version 3.0: [ADDRESS_486682] and treatment, as well as 
the mean (±SD) plasma concentration vs. scheduled time profiles for each dose level, will be 
presented graphically.   
 Pharma codynamic Analyses  
A biomarker an alysis will be performed on blood and biopsy samples collected to evaluate PD 
effects of ASN002 on inflammatory markers and cell populations. Biomarker levels will be 
compared to placebo adjusted change from baseline over time for each treatment group, and  the 
parameters will be summarized by [CONTACT_388157].  
 Other Analyses  
Descriptive summaries of baseline charact eristics, including demographic data , prior concomitant 
therapy , and of subject disposition will be presented. In addition, a list of subjects who 
discontinued from the study will be provided  
 
Protocol deviations will be summarized by [CONTACT_178467].  
 Planned Interim Analysis  
No formal interim analyses are planned for this study.  However, unblinded safety data will be 
generated and reviewed by [CONTACT_388158].  
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 63 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  9 REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS  
9.1  Local Regulations/Declaration of Helsinki  
This st udy will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and that are consistent with ICH Tripartite Guideline for GCP and the 
applicable laws and regulations of the country in which the research  is conducted, whichever 
affords the greater protection to the individual.   
9.2  Ethical Review  
It is the understanding of the sponsor that this protocol (and any amendments) as well as 
appropriate consent procedures, will be reviewed and approved by [CONTACT_2717]/EC. This board must 
operate in accordance with the current federal regulations. For sites with a local ethics committee, 
a letter or certification of approval will be sent by [CONTACT_68477] (or CRO) before 
initiation of the study and a lso whenever subsequent modifications to the protocol are made.   
9.[ADDRESS_486683], along with an assent form when required.   
 
It is the responsibility of the investigator, or a person designated by [CONTACT_093] (if acceptable 
by [CONTACT_1295]), to obtain written informed consent from each individual participating in this 
study, after adequate explanation of the aims, me thods, objectives, and potential hazards of the 
study.   
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be IR B/EC 
approved, and the subject will be asked to read and review the document. The investigator will 
explain the research study to the subject and answer any questions that may arise. A verbal 
explanation will be provided in terms suited to the subject’s co mprehension of the purposes, 
procedures, and potential risks of the study and of his or her rights as a research subject.  Subjects 
will have the opportunity to carefully review the written consent form and ask questions prior to 
signing. The subjects shou ld have the opportunity to discuss the study with their family or 
surrogates or think about it prior to agreeing to participate.  
 
The subject will sign the informed consent document prior to any procedures being done 
specifically for the study. Subjects m ust be informed that participation is voluntary and that they 
may withdraw from the study at any time  for any reason , without prejudice. A copy of the signed 
informed consent document will be given to the subjects for their records. The informed consent 
process will be conducted and documented in the source document (including the date), and the 
form signed, before the subject undergoes any study -specific procedures.  
 
The rights and welfare of the subjects will be protected by [CONTACT_388159] , LLC– Protocol ASN002AD -201 Page 64 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  their medical care will not be adversely affected if they decline to participate in this study.  
 
If new safety information results in significant changes in the risk/benefit assessment, or if any 
new information becomes available that may affect the willingness of a subject to continue to 
participate, the consent form should, if necessary, be reviewed and updated by [CONTACT_1201] /EC. All 
subjects (including those already being treated) should be informed of the new information, given 
a copy of th e revised form, and asked to give their consent to continue in the study.  
9.4  Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_388160], 
investigators, the sponsor, and regulatory authorities.  If the study is prematurely terminated or 
suspended, the princip al investigators will promptly inform study subjects and the IRB /EC, and 
will provide the reason(s) for the termination or suspension.  Study subjects will be contact[INVESTIGATOR_530], as 
applicable, and be informed of changes to study visit schedule.  
  
Circumstances tha t may warrant termination or suspension of the study include, but are not limited 
to the following:  
• Determination of unexpected, significant, or unacceptable risk to subjects  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently c omplete or evaluable  
• Scientific or corporate reasons  
 
The study may resume once concerns about safety, protocol compliance, and data quality are 
addressed and satisfy the sponsor, IRB /EC, and applicable local regulations . 
9.[ADDRESS_486684] assure that the subjects’ anonymity will be maintained and that subjects’ 
identitie s are protected from unauthorized parties. On case report forms or other documents 
submitted to the sponsor, subjects should not be identified by [CONTACT_2249], but by [CONTACT_334844]. The investigator should keep a subject enrollment log relating cod es with the names of 
subjects. The investigator should maintain in strict confidence documents not for submission to 
the sponsor  (e.g., subjects’ written consent forms).  
 
All research activities will be conducted in a setting as private as possible.  
 
The s tudy monitor, other authorized representatives of the sponsor, and representatives of the 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 65 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  IRB/EC, regulatory agencies, or pharmaceutical company supplying study product may inspect all 
documents and records required to be maintained by [CONTACT_093], in cluding but not limited to, 
medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study. 
The clinical study site will permit access to such records.  
 
The study subject’s contact [CONTACT_388161] e ach clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location 
for as long a period as dictated by [CONTACT_388162], the reviewing 
IRB/EC, institutional  policies, or sponsor requirements.  
9.6  Clinical Monitoring  
Clinical site monitoring will be conducted to ensure that the rights and well -being of trial subjects 
are protected; that the reported trial data are accurate, complete, and verifiable; and that the conduct 
of the trial is in compliance with the currently approved protocol/amendment(s), ICH GCP 
guidelines, and with applicable regulatory requirement(s). Details of clinical site monitoring will 
be documented in a Monitoring Plan.  
9.[ADDRESS_486685], data and biological 
specimen collection, documentation, and completion.   
 
Quality control (QC) procedures will be implemented beginning with the data entry system, and 
data QC c hecks, which will be run on the database, will be generated. Any missing data or data 
anomalies will be communicated to the site(s) for clarification/resolution.  
 
During the study, the sponsor or its representative will conduct monitoring visits at regular  
intervals. The monitoring visits will be conducted to ensure protocol adherence, quality of data, 
accuracy of entries on the eCRFs , study product accountability, compliance with regulatory 
requirements, and continued adequacy of the investigational site a nd its facilities.  
 
The site may be audited, monitored, or inspected by a quality assurance officer named by [CONTACT_103], by [CONTACT_1201] /EC, and/or by [CONTACT_50756]. The investigator will be given notice 
before an audit occurs and will be expecte d to cooperate with any audit and provide assistance and 
documentation (including source data) as requested. The investigational site will provide direct 
access to all trial -related sites, source data/documents, and reports for the purpose of monitoring 
and auditing by [CONTACT_271689].  
9.[ADDRESS_486686] of the study 
to be fully documented and the study data to be subsequ ently verified. These documents should be 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 67 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  10 REFERENCES  
1. Williams HC. Atopic eczema. Bmj. 1995;311(7015):1241 -2. 
2. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. 
Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment 
of atopic dermatitis with topi[INVESTIGATOR_12491]. J Am Acad Dermatol. 2014;71(1):116 -32. 
3. Leung DY, Guttman -Yassky E. Deciphering the complexities of atopic dermatitis: shifting 
paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769 -79. 
4. Silverberg JI. Persistence of childhood eczema into adulthood. JAMA Dermatol. 
2014;150(6):591 -2. 
5. Cabanillas B, Brehler AC, Novak N. Atopic dermatitis phenotypes and the need for 
personalized medicine. Curr Opin Allergy Clin Immunol. 2017;17(4):309 -15. 
6. Lewis -Jones S. Quality of life and childhood atopic dermatitis: the misery of living with 
childhood eczema. International journal of clinical practice. 2006;60(8):984 -92. 
7. Marciniak J, Reich A, Szepi[INVESTIGATOR_22938]. Quality of Life of Parents of Children wi th Atopic 
Dermatitis. Acta Derm Venereol. 2017;97(6):711 -4. 
8. Mochizuki H, Schut C, Nattkemper LA, Yosipovitch G. Brain mechanism of itch in atopic 
dermatitis and its possible alteration through non -invasive treatments. Allergol Int. 2017;66(1):14 -
21. 
9. Bieber T, D'Erme AM, Akdis CA, Traidl -Hoffmann C, Lauener R, Schappi G, et al. 
Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we 
go? J Allergy Clin Immunol. 2017;139(4S):S58 -S64. 
10. Brunner PM, Guttman -Yassky E , Leung DY. The immunology of atopic dermatitis and its 
reversibility with broad -spectrum and targeted therapi[INVESTIGATOR_014]. J Allergy Clin Immunol. 
2017;139(4S):S65 -S76. 
11. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. 
Guidelines of  care for the management of atopic dermatitis: section 1. Diagnosis and assessment 
of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):[ADDRESS_486687] 
Dermatol. 2017;137(1):18 -25. 
13. Guttman -Yassky E, Ungar B, Malik K, Dickstein D, Suprun M, Estrada YD, et al. 
Molecular signatures order the potency of topi[INVESTIGATOR_388130]-inflammatory drugs in patients 
with atopic dermatitis. J Allergy Clin Immunol. 2017;140(4):1032 -42 e13.  
14. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets 
and drugs. Drug Discov Today. 2010;15(13 -14):517 -30. 
15. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of 
Janus kinases. Immunol Rev. 2008;223:132 -42. 
16. Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman -Yassky E, et al. Cellular 
and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin 
Immunol. 2016;138(2):336 -49. 
17. Kyttaris VC, Tsokos GC. Syk kinase as a treatment target for therapy in autoimmune 
diseases. Clin Immunol. 2007;124(3):235 -7. 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 68 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  18. Tofte S, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin JM. Posters - P48 - Eczema 
area and severity index (EASI): A new tool to evaluate atopic dermatitis. [abstract]. J Eur Acad 
Dermatol Venereol. 1998;11(suppl 2):S197.  
19. Rullo VE, Segato A, Kirsh A, Sole D. Severity scoring of atopic dermatitis: a comparison 
of two scoring systems. Allergol Immunopathol (Madr). 2008;36(4):205 -11. 
20. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the 
European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1) :23-31. 
21. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus 
intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating 
scale and verbal rating scale in 471 patients with chron ic pruritus. Acta Derm Venereol. 
2012;92(5):502 -7. 
22. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5 -D itch scale: a new measure of pruritus. 
Br J Dermatol. 2010;162(3):587 -93. 
23. Charman CR, Venn AJ, Williams HC. The patient -oriented eczema measure: devel opment 
and initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Archives of dermatology. 2004;140(12):1513 -9. 
24. The patient -oriented eczema measure: development and initial validation of a new tool for 
measuring atopic eczema severity from the patients' perspective - correction. Archives of 
Dermatology. 2005;141(3):381.  
25. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato -
Venereologica Supplementum. 1980;92:44 -7. 
 
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 69 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX A: Diagnostic Criteria for Atopic Dermatitis  
Per Inclusion Criterion 2, a subject is to have a clinical diagnosis of atopic dermatitis according to 
the criteria of Hanifin and Rajka.(25) The criteria are as follows:  
 
Major Criteria (must have at least three)  
• Pruritus  
• Typi[INVESTIGATOR_22784]:  
– Adults: flexural lichenification or linearity  
– Children and infants: involvement of facial and extensor surfaces  
• Chron ic or chronically relapsing dermatitis  
• Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)  
 
Minor Criteria (must have at least three)  
• Xerosis  
• Ichthyosis/keratosis pi[INVESTIGATOR_22785]/palmar hyperlinearity  
• Immediate (Type 1) skin test rea ctivity  
• Elevated serum IgE  
• Early age at onset  
• Tendency to skin infections ( Staphylococcus aureus , herpes simplex)/impaired cellular 
immunity  
• Tendency to nonspecific hand/foot dermatitis  
• Nipple eczema  
• Cheilitis  
• Recurrent conjunctivitis  
• Dennie -Morgan infraorbital fold  
• Keratoconus  
• Anterior subcapsular cataracts  
• Orbital darkening  
• Facial pallor/erythema  
• Pi[INVESTIGATOR_80166]  
• Anterior neck folds  
• Itch when sweating  
• Intolerance to wool and lipid solvents  
• Perifollicular accentuation  
• Food intolerance  
• Course influenced by [CONTACT_222224]/emotional factors  
• White de rmographi sm/delayed blanch  
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 70 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX B: Eczema Area and Severity Index  
 
Four anatomic sites —head, upper extremities, trunk , and lower extremities —are assessed for 
erythema, induration /infiltration  (papules), excoriation , and lichenification as seen on the day of 
the examination. The severity of each sign is assessed using a 4 -point scale  (half steps are 
allowed) : 
 
• 0 = none  
• 1 = mild 
• 2 = moderate  
• 3 = severe  
 
The area affected by [CONTACT_125081] a given anatomic site is estimated as a percentage of 
the total area of that anatomic site and assigned a numerical value according to the degree of atopic 
dermatitis involvement as follows:  
 
• 0 = no involvement  
• 1 = <10%  
• 2 = 10 % to <30%  
• 3 = 30% to <50%  
• 4 = 50 % to <70%  
• 5 = 70 % to <90%  
• 6 = 90 % to 100%  
 
The EASI score is obtained by [CONTACT_388163]:  
 
EASI = 0.1 ( Eh + I h + Exh + L h) A h + 0.2 ( Eu + Iu + Exu + Lu) A u + 0.3  (Et + It 
+ Ext + Lt) A t + 0.4 ( El + I l + Exl + Ll) Al 
 
Where E, I, Ex, L, and A denote erythema, induration, excoriation, lichenification and area, 
respectively, and h, u, t, and l denote head, upper extremities, trunk, and lower extremities, 
respectively.   
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 71 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX C: vIGA -ADTM 
  

Asana BioSciences , LLC– Protocol ASN002AD -201 Page 72 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX D: Scoring Atopic Dermatitis  - SCORAD  
 
Six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) 
are selected to evaluate the atopic dermatitis severity. The intensity of each item is graded using a 
4-point scale  (half steps not allowed) : 
 
• 0 = absence  
• 1 = mild 
• 2 = moderate  
• 3 = severe  
 
The area chosen for grading must be representative (average intensity) for each item. The 
individual intensity ratings for each item will then be added (ranging from 0 -18) and multiplied by 
3.5, giv ing a maximal score of 63.  
 
The overall BSA affected by [CONTACT_388164] (from 0 % to 100%) and divided by 5. 
One subject ’s palm represents 1% of his  or her total BSA. The maximum is 20.  
 
Subjective items include loss of sleep and the occurren ce of pruritus. These are evaluated by [CONTACT_388165] s to indicate on the 10 -cm scale (0 -10) of the assessment form the point corresponding to 
the average value for the last 3 days/nights. The combined maximum score of these two is 20.  
 
The sum of the meas ures above  represents the SCORAD , which can vary from 0 to 103. If the 
subjective scores of pruritus and loss of sleep are excluded, the SCORAD becomes objective 
SCORAD (score range 0 -83). 
  
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 73 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX E: Patient -Oriented Eczema Measure  
 

Asana BioSciences , LLC– Protocol ASN002AD -201 Page 74 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX F: Patient -Oriented Eczema Measure  
 
Subject ID #: ___ ___ - ___ ___ ___   Subject Initials: ___ ___ ___  
 
Visit Day: ___________   Visit Date (dd -mmm -yyyy):______________  
 
Please circle one response for each of the seven questions below about your eczema. Please 
leave blank any questions you feel unable to answer.  
 
1. Over the last week, on how many days has your skin been itchy because of your eczema?  
No days  1-[ADDRESS_486688] week, on how many nights has your sleep been disturbed because of your 
eczema?  
No days  1-[ADDRESS_486689] week, on how many days has your skin been bleeding because of your 
eczema?  
No days  1-[ADDRESS_486690] week, on how many days has your skin been weepi[INVESTIGATOR_388131]?  
No days  1-[ADDRESS_486691] week, on how many days has your skin been cracked because of your 
eczema?  
No days  1-[ADDRESS_486692] week, on how many days has your skin been flaking off because of your 
eczema?  
No days  1-[ADDRESS_486693] week, on how many days has your skin felt dry or rough because of your 
eczema?  
No days  1-2 days  3-4 days  5-6 days  Every day  
 
 
 
 
© CR Charman, AJ Venn, HC Williams, December 2004.  
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 75 of 76  
Protocol version 3.0: 07 February  2019 
 
 
 
 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX G: Dermatology Life Quality Index  
 
Subject ID #: ___ ___ - ___ ___ ___   Subject Initials: ___ ___ ___  
 
Visit Day: ___________   Visit Date (dd -mmm -yyyy):______________  
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER 
THE LAST WEEK.  Please check one box for each question.  
 
1.  Over the last week, how itchy , sore, painful  or stinging  has your 
skin been?  Very much  
A lot  
A little  
Not at all  
 
 
 
  
2.  Over the last week, how embarrassed  or self conscious  have you 
been because of your skin?  Very much  
A lot  
A little  
Not at all  
 
 
 
  
3.  Over the last week, how much has your skin interfered with you 
going shoppi[INVESTIGATOR_388132]?  Very much  
A lot  
A little  
Not at all  
 
 
 
  
 
 
Not relevant 
  
4.  Over the last week, how much has your skin influenced the 
clothes  you wear?  Very much  
A lot  
A little  
Not at all  
 
 
 
  
 
 
Not relevant 
  
5.  Over the last week, how much has your skin affected any social  
or leisure  activities?     Very much  
A lot  
A little 
Not at all  
 
 
 
  
 
 
Not relevant 
  
6.  Over the last week, how much has your skin made it difficult for 
you to do any sport ? 
 Very much  
A lot  
A little  
Not at all  
 
 
 
  
 
 
Not relevant 
  
7.  Over the last week, has your skin prevented you from working  or 
studying ? Yes 
No 
 
 
  
Not relevant 
  
If “No,” over the last week how much has your skin been a 
problem at work  or studying ? A lot  
A little  
Not at all  
 
 
  
 
 
Asana BioSciences , LLC– Protocol ASN002AD -201 Page 76 of 76  
Protocol version 3.0: [ADDRESS_486694] week, how much has your  skin created 
problems with your partner  or any of your close friends or 
relatives ?   Very much  
A lot  
A little  
Not at all  
 
 
 
  
 
 
Not relevant 
  
9.  Over the last week, how much has your  skin caused any 
sexual difficulties ?  Very much  
A lot  
A little  
Not at all  
 
 
 
  
 
 
Not relevant 
  
[ADDRESS_486695] week, how much of a problem has the treatment  for 
your skin been, for example by [CONTACT_80243], or by 
[CONTACT_78469]?  Very much  
A lot  
A little  
Not at all  
 
 
 
  
 
 
Not relevant 
  
©AY Finlay, GK Khan, April [ADDRESS_486696] answered EVERY question. Thank you.  
 